TY - JOUR
T1 - Sandmeyer reaction repurposed for the site-selective, non-oxidizing radioiodination of fully-deprotected peptides
T2 - Studies on the endogenous opioid peptide α-neoendorphin
AU - Pickett, Julie E.
AU - Nagakura, Kunihiko
AU - Pasternak, Anna R.
AU - Grinnell, Steven G.
AU - Majumdar, Susruta
AU - Lewis, Jason S.
AU - Pasternak, Gavril W.
N1 - Funding Information:
This work was supported, in part, by research Grants (DA06241 and DA02615) to GWP and a training grant (T32DA07274) to JEP from the National Institute on Drug Abuse and a core grant (CA 08748) from the National Cancer Institute of the National Institutes of Health. We would like to thank MSKCC’s Radiochemistry and Imaging Sciences Service for use of their facilities. We would also like to thank everyone who contributed their time and energy in the preparation of this manuscript.
PY - 2013/8/1
Y1 - 2013/8/1
N2 - Standard radioiodination methods lack site-selectivity and either mask charges (Bolton-Hunter) or involve oxidative reaction conditions (chloramine-T). Opioid peptides are very sensitive to certain structural modifications, making these labeling methods untenable. In our model opioid peptide, α-neoendorphin, we replaced a tyrosyl hydroxyl with an iodine, and in cell lines stably expressing mu, delta, or kappa opioid receptors, we saw no negative effects on binding. We then optimized a repurposed Sandmeyer reaction using copper(I) catalysts with non-redoxing/non-nucleophilic ligands, bringing the radiochemical yield up to around 30%, and site-selectively incorporated radioactive iodine into this position under non-oxidizing reaction conditions, which should be broadly compatible with most peptides. The 125I- and 131I-labeled versions of the compound bound with high affinity to opioid receptors in mouse brain homogenates, thus demonstrating the general utility of the labeling strategy and of the peptide for exploring opioid binding sites.
AB - Standard radioiodination methods lack site-selectivity and either mask charges (Bolton-Hunter) or involve oxidative reaction conditions (chloramine-T). Opioid peptides are very sensitive to certain structural modifications, making these labeling methods untenable. In our model opioid peptide, α-neoendorphin, we replaced a tyrosyl hydroxyl with an iodine, and in cell lines stably expressing mu, delta, or kappa opioid receptors, we saw no negative effects on binding. We then optimized a repurposed Sandmeyer reaction using copper(I) catalysts with non-redoxing/non-nucleophilic ligands, bringing the radiochemical yield up to around 30%, and site-selectively incorporated radioactive iodine into this position under non-oxidizing reaction conditions, which should be broadly compatible with most peptides. The 125I- and 131I-labeled versions of the compound bound with high affinity to opioid receptors in mouse brain homogenates, thus demonstrating the general utility of the labeling strategy and of the peptide for exploring opioid binding sites.
KW - Endogenous opioid peptide
KW - I-125
KW - I-131
KW - Opioid receptor binding
KW - Peptide radioiodination
UR - http://www.scopus.com/inward/record.url?scp=84879685926&partnerID=8YFLogxK
U2 - 10.1016/j.bmcl.2013.05.090
DO - 10.1016/j.bmcl.2013.05.090
M3 - Article
C2 - 23796454
AN - SCOPUS:84879685926
SN - 0960-894X
VL - 23
SP - 4347
EP - 4350
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
IS - 15
ER -